相似文献
1
Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined.
Transl Lung Cancer Res. 2020 Oct;9(5):1732-1735. doi: 10.21037/tlcr-20-362.
2
Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.
Lung Cancer. 2021 Jun;156:59-67. doi: 10.1016/j.lungcan.2021.04.013. Epub 2021 Apr 19.
3
Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Cancer Med. 2020 Jan;9(2):432-439. doi: 10.1002/cam4.2716. Epub 2019 Nov 20.
4
Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
Lung Cancer. 2018 May;119:112-119. doi: 10.1016/j.lungcan.2018.02.011. Epub 2018 Feb 21.
5
Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?
Expert Opin Pharmacother. 2008 Jun;9(8):1321-37. doi: 10.1517/14656566.9.8.1321.
6
Chemotherapeutic management of stage IV non-small cell lung cancer.
Chest. 2003 Jan;123(1 Suppl):226S-243S. doi: 10.1378/chest.123.1_suppl.226s.
7
Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.
Lung Cancer. 2020 Aug;146:160-164. doi: 10.1016/j.lungcan.2020.05.038. Epub 2020 Jun 6.
8
Optimal drugs for second-line treatment of patients with small-cell lung cancer.
Expert Opin Pharmacother. 2016;17(7):969-76. doi: 10.1517/14656566.2016.1154539. Epub 2016 Feb 29.
9
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Jpn J Clin Oncol. 2015 Jul;45(7):670-6. doi: 10.1093/jjco/hyv054. Epub 2015 Apr 15.
10
Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
Clin Ther. 2017 Jun;39(6):1146-1160. doi: 10.1016/j.clinthera.2017.04.010. Epub 2017 May 18.
引用本文的文献
1
FOXM1 targeting alters AURKB activity and reshapes antitumor immunity to curb the progression of small cell lung cancer.
Res Sq. 2025 Jul 1:rs.3.rs-6960266. doi: 10.21203/rs.3.rs-6960266/v1.
2
Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer.
Front Oncol. 2024 Jul 31;14:1303268. doi: 10.3389/fonc.2024.1303268. eCollection 2024.
3
Combined PARP and PD-L1 inhibition: a promising treatment option for relapsed small-cell lung cancer.
J Thorac Dis. 2024 Jun 30;16(6):4075-4078. doi: 10.21037/jtd-24-269. Epub 2024 Jun 25.
4
Immunotherapy-Related Cystitis: Case Report and Review of the Literature.
Onco Targets Ther. 2021 Jul 31;14:4321-4328. doi: 10.2147/OTT.S321965. eCollection 2021.
本文引用的文献
1
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol. 2020 Sep;21(9):1224-1233. doi: 10.1016/S1470-2045(20)30461-7.
2
Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis.
Transl Lung Cancer Res. 2019 Dec;8(6):829-837. doi: 10.21037/tlcr.2019.10.21.
3
Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study.
Acta Oncol. 2020 Apr;59(4):388-394. doi: 10.1080/0284186X.2019.1711165. Epub 2020 Jan 7.
4
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.
J Thorac Oncol. 2020 Mar;15(3):426-435. doi: 10.1016/j.jtho.2019.10.004. Epub 2019 Oct 17.
5
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
6
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Lung Cancer. 2019 Oct;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. Epub 2019 Aug 29.
7
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
Lung Cancer. 2019 Apr;130:216-225. doi: 10.1016/j.lungcan.2019.02.026. Epub 2019 Feb 25.
8
Immunotherapy in extensive small cell lung cancer.
Exp Hematol Oncol. 2019 Feb 4;8:5. doi: 10.1186/s40164-019-0129-x. eCollection 2019.
9
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.
J Thorac Oncol. 2019 May;14(5):903-913. doi: 10.1016/j.jtho.2019.01.008. Epub 2019 Jan 18.
10
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
Zotero 插件